Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $32 and keeps a Sell rating on the shares. The firm updated the company’s model following the recent closure of the deal with Novartis for PTC518 as well as recent pipeline updates. However, Citi believes PTC’s upcoming catalysts have some risk.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald
- PTC Therapeutics price target raised to $50 from $46 at TD Cowen
- PTC Therapeutics price target lowered at Cantor Fitzgerald, a top pick in 2025
- PTC Therapeutics Surpasses Revenue Guidance for 2024
- PTC Therapeutics provides potential key clinical, regulatory events in 2025